Pre-B-cell leukemia homeobox (PBX) transcription factors are known to regulate organogenesis, but their molecular targets and function in midbrain dopaminergic neurons (mDAn) as well as their role in neurodegenerative diseases are unknown. Here, we show that PBX1 controls a novel transcriptional network required for mDAn specification and survival, which is sufficient to generate mDAn from human stem cells. Mechanistically, PBX1 plays a dual role in transcription by directly repressing or activating genes, such as Onecut2 to inhibit lateral fates during embryogenesis, Pitx3 to promote mDAn development, and Nfe2l1 to protect from oxidative stress. Notably, PBX1 and NFE2L1 levels are severely reduced in dopaminergic neurons of the substantia nigra of Parkinson's disease (PD) patients and decreased NFE2L1 levels increases damage by oxidative stress in human midbrain cells. Thus, our results reveal novel roles for PBX1 and its transcriptional network in mDAn development and PD, opening the door for new therapeutic interventions.
Introduction
Midbrain dopaminergic neurons (mDAn) play a central role in the modulation of several brain functions, including voluntary movements, emotion, and cognition. The progressive degeneration of substantia nigra (SN) mDAn gives rise to some of the main motor features of PD (Lees et al, 2009) . Current treatments for PD are symptomatic and there is a need for therapies capable of changing the course of this disease. The PBX family of transcription factors is composed of four members in mammals (PBX1-4) (Moens & Selleri, 2006; Longobardi et al, 2013) . Expression of Pbx genes has been detected in both the mouse and human midbrain as well as mDAn (Thompson et al, 2006; Yin et al, 2009; Ganat et al, 2012; Sgado et al, 2012; Veenvliet et al, 2013) . However, to date only a very mild mDAn axon guidance phenotype has been described in Pbx1 null embryos (Sgado et al, 2012) . Thus, the function and precise role of different PBX family members on mDAn remains largely unexplored. Moreover, the mechanism of action and molecular targets of PBX transcription factors in mDAn, as well as any role in neurodegenerative diseases, such as PD, remains unknown.
The development of mDAn is controlled by a combination of cell extrinsic and intrinsic signals (Prakash & Wurst, 2006; Ribes et al, 2010; Arenas et al, 2015) . One such pathway is that formed by SHH, which regulates and is regulated by FOXA2, a forkhead/winged helix transcription factor required for mDAn development (Ferri et al, 2007) . A second main pathway involves WNT1, which regulates and is regulated by LMX1A, a LIM homeodomain transcription factor required for mDAn specification . Notably, LMX1A forms an autoregulatory loop together with LMX1B and WNT1, and directly regulates the expression of the orphan nuclear receptor Nurr1/Nr4a2 and the paired-like homeodomain transcription factor 3 (Pitx3) gene (Chung et al, 2009) . Both Nurr1 and Pitx3 are required for mDA neuron differentiation and survival (Zetterstrom et al, 1997; Nunes et al, 2003; Smidt et al, 2004; Maxwell et al, 2005) . While LMX1A labels all the cells in the mDA lineage, from proliferating progenitors to postmitotic neuroblasts and mDAn , NURR1 labels all postmitotic cells, from mDA neuroblasts to neurons. The very first mDA neuroblasts in mice are detected at embryonic day (E) 10, as LMX1A We hereby show that the Pbx1 homeobox gene is a novel intrinsic determinant important for the specification and survival of mDA neurons. PBX1 is present in a subpopulation of NURR1 + neuroblasts and in all mDAn, where it plays a dual role in transcription by directly activating genes such as Pitx3, to promote mDAn development, or repressing genes such as Onecut2, to inhibit lateral fates in the midbrain floor plate (mFP). We also found that PBX1 directly increases the expression of a neuroprotective gene activated by oxidative stress, Nfe2l1, which is known to regulate mitochondrial function and proteasomal activity. Notably, a reduction of PBX1 and NFE2L1 levels was detected in the nuclei of mDAn in the substantia nigra (SN) of PD patients. Moreover, we found that decreased levels of NFE2L1 results in increased vulnerability of human midbrain cells to oxidative stress. Thus, our results reveal novel roles of PBX1 and its transcriptional network in mDAn development and PD, opening the door for the future development of novel therapeutic strategies.
Results

PBX1A is present in the developing mDAn and type 2 neuroblasts
Transcriptome analyses (RNA-Seq) of the mFP at E12.5, compared to adjacent anterior and posterior structures and the dorsal midbrain, revealed enriched expression of the transcription factor Pbx1 together with markers of mDAn such as Th, the rate-limiting enzyme for the synthesis of DA, and Pitx3, a factor required for the survival of mDAn of the SN (Nunes et al, 2003; Smidt et al, 2004; Maxwell et al, 2005) (Fig 1A) . In situ hybridization analyses at E12.5 confirmed that Pbx1 was highly expressed from rostral to caudal levels in the intermediate and marginal zones of the mFP, while Pbx3 transcripts were only weakly detectable in the LMX1A + mFP and then only at the rostral level (Figs 1B and EV1) . A developmental time-course analysis revealed that the first PBX1 + cells appeared in the mFP at around E10, a few hours before the first TH + mDAn (at E10.5), and that all TH + cells at E12.5 in the marginal zone contained PBX1 + nuclei (Fig 1C) . Examination of mDA neuroblasts characterized by the expression of Nurr1/Nr4a2, an orphan nuclear receptor required for the development of mDAn (Zetterstrom et al, 1997) , revealed that only a subpopulation of NURR1 + neuroblasts become PBX1 + at E11.5 (purple nuclei, Fig 1D) . PBX1 was also present in all PITX3 + mDAn, but PITX3 + labeled only a fraction of all PBX1 + cells in the mFP at E12.5
( Fig 1E) . Analysis of the two main PBX1 isoforms (PBX1A and B), differing in their C-terminus domain (Moens & Selleri, 2006) , revealed that only PBX1A, the full-length isoform, is present in mDAn during embryonic development in neuroblasts type 2 and mDAn (Fig 2A and B and Appendix Fig S1) . To examine the relevance of these findings to human midbrain development, we undertook similar studies in human embryos. Unlike a previous study, which showed a broad distribution of PBX1 + cells in week 6-8 human ventral midbrain (VM) (Ganat et al, 2012) , our analysis of 7-week human embryonic VM tissue shows that all TH + and some cells in the intermediate zone were PBX1 + (Fig 2C) , suggesting a conserved role of PBX1 in mouse and human mDAn development.
In agreement with the study by Ganat et al (2012) , PBX1 was found in mDAn of the ventral tegmental area (VTA, A10) and SN (A9) of adult mice (Fig 2D) , suggesting a possible conserved function from development through to adulthood. Fig EV2B) , a transcription factor required for mDA neurogenesis (Kele et al, 2006) , or in SOX6 and OTX2 (Fig EV2C) , two transcription factors involved in SN vs. VTA subtype specification, respectively (Di Salvio et al, 2010; Panman et al, 2014) . Together, our data indicate that there is no alteration in mDA neurogenesis or neuron subtype specification, but rather a specific defect in the differentiation of NURR1 A Tru-Seq RNA sequence analysis of E12.5 midbrain floor plate (mFP), midbrain roof-plate (mRP), anterior (A, adjacent anterior FP), and posterior (P, adjacent posterior FP). Pbx1 is enriched in the midbrain FP, together with Th and Pitx3. Lower levels of Pbx3 are also expressed in the mFP. Gdf7 and Wnt1 are restricted to the mRP at E12.5. B Pbx1 is expressed in the intermediate (IZ) and marginal zones (MZ), but not the ventricular zone (VZ), of the mFP at E12.5, as detected by in situ hybridization. C PBX1 is first detected in the ventro-lateral part of the LMX1A + domain at E10, preceding the birth of the first (TH + ) mDA neurons at E10. Fig 3C) . These results showed a defect in the differentiation of mDAn at E14.5, which followed the pattern of nuclear CRE and recombination (Fig EV3A and B) ) cells, a marker of cellular damage and apoptosis, both at E14.5 (cHet = 43 AE 8.7 vs. cKO = 71 AE 4.4, mean AE SD, P-value 0.016) and E18.5 (Fig 3E) . In addition, staining for 5HT (serotoninergic neurons) showed no major differences in cKO vs. cHET embryos at E18.5 (Fig EV2D) , indicating that there is no anterior-posterior misspecification. The loss of TH + neurons was also reflected by a loss of TH immunoreactive fibers in the striatum of cKO at E18.5 (Fig EV3D) . (Falk et al, 2012) , a source of rosette-type neural stem cells with extensive self-renewal and stable neurogenic capacities (Koch et al, 2009) , were differentiated using a basic 8 day differentiation protocol (Fig 4A) . Lentivirus-mediated overexpression of human PBX1 was sufficient to increase the final number of TH + neurons compared to control (Fig 4B) . While PBX1 expression did not change the total number of Dapi + cells, a remarkable 2.3-fold increase in TH + cells was detected (Fig 4B and C) . TH + cells in the PBX1-overexpressing condition were also positive for mDA lineage markers such as LMX1A and PITX3 (Fig 4D) . Thus, our results indicate that PBX1 can improve the generation of mDAn from hNES cells, opening the door to new future avenues to improve mDAn replacement therapies for PD (Arenas et al, 2015) .
Identification of direct PBX1 target genes
To identify the molecular mechanisms by which PBX1 regulates mDAn development, we performed chromatin immunoprecipitation sequencing (ChIP-seq) on E12.5 mouse VM tissue using a PBX1 antibody validated for immunoprecipitation ( Fig EV4A) . Our analysis identified a PBX1 binding site composed of a 10-nucleotide motif (A) separated by 8-11 nucleotides from a 5-nucleotide motif (B) (Fig 5A) . A similar 10-nucleotide motif was recently reported, where the binding capacity of PBX1 was demonstrated using an electrophoretic mobility assay (Ferretti et al, 2011; Penkov et al, 2013) . Most PBX1-binding sites were in close proximity to transcription starting sites (TSS) (Fig EV4B and C) . The enrichment profiles of some PBX1-binding sites and their corresponding genomic regions are shown in Figs 5B and EV4D and E. Enriched gene categories were related to signal transduction (P-value 10 À13 ), RNA metabolic processes (P-value 10 À10 ), as well as transcription and response to stress (P-value 10 À7 ) ( Fig EV4F) .
We next combined our RNA-Seq analysis of VM tissue at E12.5 with our ChIP-seq data in order to identify possible direct PBX1 A PBX1A is the isoform detected in the TH + NURR1 + mDA neurons at E12.5.
B Scheme representing the LMX1A, NURR1, PBX1, and TH/PITX3 domains in the embryonic VM at E11.5-12.5. C Immunofluorescence analysis of 7-week-old human VM tissue showing that all mDAn are positive for PBX1, suggesting a conserved role for this factor in the development of these neurons in mice and humans. D PBX1 is also present in TH + adult mDA neurons of the substantia nigra (SN) and ventral tegmental area (VTA). E Schematic representation of sequential markers expressed in the mDA lineage from progenitors (P), primary neuroblasts (Nb 
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The EMBO Journal target genes differentially expressed in the VM. Gene Set Enrichment Analysis (GSEA) showed a strong correlation between the cistrome and transcriptome (P-value < 0.001, q-value < 0.005). Moreover, the highly correlated genes were either enriched (green) or depleted (red) in the E12.5 VM, suggesting a possible dual role of PBX1 as both an activator and repressor of transcription in the VM, as described for other tissues (Asahara et al, 1999; Saleh et al, 2000) . Most of the PBX1 loci were located in the proximity of a single gene (87.6%, 177 of 202) (Fig EV5A and B (Suske, 1999) . Moreover, using an unbiased bioinformatics analysis of the promoter regions of PBX target genes for transcription factor binding site enrichment (Kwon et al, 2012) , we found only a few binding sites exclusive for activated or repressed loci (Fig EV5D-F) .
The most noticeable was the presence of a binding site for NR4A2/ NURR1 at a repressor locus, suggesting a possible concerted action of PBX1 and NR4A2/NURR1 to repress common target genes. Twenty-nine genes with PBX1 binding sites in close proximity to their TSS (À5,000 to + 500 bp) were differentially up-regulated or down-regulated in the mFP vs. adjacent regions and midbrain roofplate (t-test q-value < 0.05) (Figs 5C and EV6) . Moreover, these 29 genes were positioned in the leading edges of the curve generated by GSEA (red dots in Fig 5D) , indicating a dual activator-repressor activity of PBX1. The highest enriched gene in the list was the homeobox gene Pitx3. Specific binding of PBX1 to a Pitx3-associated region identified in our ChIP-Seq was confirmed by ChIP-PCR ( Fig 5E) . As conditional double KO embryos showed a drastic reduction of TH + cells, we decided to analyze embryos with only one allele of Pbx3. Accordingly, Pbx1 À/À ;Pbx3 +/À embryos showed decreased levels of PITX3 and a 40% reduction in the number of PITX3 + cells at E12.5, which was more prominent in the midline and basal plate ( Fig 5F and Appendix Fig S4) . The most downregulated gene in our list was the homeobox gene Onecut2, which is broadly expressed in the central nervous system (Francius & Clotman, 2010; Espana & Clotman, 2012; Stam et al, 2012; Wu et al, 2012) , but its deletion does not lead to abnormalities in mDAn development (Espana & Clotman, 2012) . We found that Onecut2 is expressed in the midbrain from the basal to the roof-plate, but not in the mFP (Appendix Fig S5) . However, in Pbx1 The Nfe2l1 gene (nuclear factor erythroid-derived 2-like 1, also known as Nrf1 and Tcf11) was the third most enriched target gene of PBX1 in the VM (Fig 5C) . ChIP-PCR confirmed that PBX1 binds to a regulatory region in close proximity to the TSS of Nfe2l1 (60 bp distance) in E12.5 mouse VM (Fig 5E) . Forced expression of human PBX1 with lentiviral particles increased protein levels of NFE2L1 by 1.5-fold, compared to the control condition, in a mouse SN mDAn cell line (SN4741 cells (Son et al, 1999) ) (Appendix Fig S6A) . Multiple cells in the VM, including TH + neurons, were found to be NFE2L1 + at E12.5 (Fig 6A) . To examine whether the expression of Nfe2l1 in TH + cells is regulated by PBX1, we analyzed the VM of Pbx1 À/À ;Pbx3 +/À embryos and found a near complete loss of NFE2L1 in TH + neurons at E12.5 (Fig 6B) , but not in PBX1-free structures such as the branchial arches (Appendix Fig S6B) , underlining the specificity of the regulation of NEF2L1 by PBX1/3 in mDAn. However, the function of NFE2L1 is not limited to mDAn as deletion of Nfe2l1 impairs cell survival in other cell types and results in embryonic lethality (Farmer et al, 1997) .
Nfe2l genes encode basic leucine zipper transcription factors that bind to antioxidant response elements to regulate the expression of cytoprotective target genes in response to oxidative stress (Jennings et al, 2012) . We thus examined whether NFE2L1 plays a role in preventing oxidative stress in human mDAn. hNES cells were differentiated for 8 days, infected with lentiviral particles containing a combination of three different NFE2L1 shRNAs to block NFE2L1 expression (Appendix Fig S6C) , and 4 days later were treated for 12 hours with H 2 O 2 (Appendix Fig S6D) . We found that cells exposed to NFE2L1 shRNAs showed reduced NFE2L1 levels (Appendix Fig S6C) The EMBO Journal PBX1 controls midbrain dopaminergic development J Carlos Villaescusa et al our results indicate that the PBX1-NFE2L1 axis plays a role in preventing damage by oxidative stress in human mDAn.
The PBX1-NFE2L1 pathway is disrupted in PD patients
Nfe2l1 has been also found to regulate genomic stability (Oh et al, 2012) and increase proteasome transcription and activation in response to cell stressors such as proteasome inhibition (Steffen et al, 2010) or PARK2/Parkin-mediated mitophagy (Furuya et al, 2014) , two functions impaired in PD (Scarffe et al, 2014; Pickrell & Youle, 2015) . To examine the role of NFE2L1 in vivo and its possible implication in PD, we next examined human postmortem tissue samples from both PD brains and aged-matched controls with no other brain pathology for the presence of nuclear PBX1 and NFE2L1. We only considered sections from patients and controls in which nuclear immunoreactivity for NFE2L1 antibody was clearly detected, and used consecutive sections for PBX1 analyses. We found that the levels of PBX1 in the nuclei of neuromelanin-positive (NM + ) cells in the SN were significantly reduced in PD patients compared to controls (dark blue/black precipitate, Fig 6E and F) . NFE2L1 showed strong nuclear punctuate staining in 20-50% of the nuclei of NM + cells in the SN of control donors (Fig 6G-I ). To our surprise, the number of NM + neurons with nuclear NFE2L1 staining was dramatically reduced or completely absent in PD patients (0-10%) (Fig 6G-I ). This effect was specific to the NM + cells of the SN since other midbrain cells outside the mDA domain remained NFE2L1 + (Appendix Fig S6F) . This result indicated that the PBX1-NFE2L1 pathway is impaired in mDAn of the SN in PD patients.
Discussion
Our study identifies Pbx1 as a novel intrinsic determinant required for the specification and survival of mDAn. Notably, deletion of Pbx1 was compensated by an upregulation of Pbx3, which is otherwise only expressed at low levels in the anterior midbrain and is not required per se for mDAn development. Pbx3 upregulation partially compensated for the loss of Pbx1, as indicated by the strong phenotype in compound mutant mice. Pbx1 and in its absence Pbx3, are required for the correct medio-lateral specification, differentiation and survival of mDA type 2 neuroblasts and mDAn during development. Mechanistically, we found that PBX1A binds to a DNA sequence highly conserved in vertebrates (Figs 5A and EV6A), which is formed by two motifs: a PBX1 binding site and a small CCAAT box extension, which may be bound by other transcription factors such as C/EBPs (CCAAT-enhancer-binding proteins), also known to control neurogenesis and neuronal differentiation (Menard et al, 2002; Cortes-Canteli et al, 2011) . Our combined ChIP-Seq and RNASep analysis revealed that PBX1 has a dual transcriptional role in mDAn, which involves both directly repressing the expression of Onecut2 (to repress lateral fates) as well as activating the expression of both Pitx3 (to promote mDAn differentiation) and Nfe2l1 (to promote mDAn survival). Our results thus indicate that PBX1 controls a full transcriptional program essential for different aspects of mDAn development and maintenance.
Current therapies for PD focus on correcting or balancing neurotransmitter levels or function by different means, which result in symptomatic relief, but do not change the course of the disease. The design of novel strategies to treat PD is currently limited by our incomplete knowledge of the mechanisms that control the development and maintenance of mDAn as well as the pathogenic pathways driving the disease. By unraveling some of these mechanisms, our work may contribute to the development of such therapies. For instance, the finding that expression of PBX1 in human neural stem cells improves the generation of mDAn suggests a possible application of PBX1 to improve current protocols for the generation of mDAn from pluripotent stem cells (Kriks et al, 2011; Kirkeby et al, 2012) , which could lead to improvements for cell replacement therapy or disease modeling of PD. We also report that PBX1 directly controls the expression of an antioxidant transcription factor, Nfe2l1, which counteracts oxidative stress, mitochondrial dysfunction, and proteasome impairment (Hirotsu et al, 2012; Furuya et al, 2014; Bugno et al, 2015) . Our results show a dramatic reduction or complete absence of nuclear PBX1 and NFE2L1 in neuromelanin + neurons of the substantia nigra of PD patients, pointing to a possible defect in the PBX1-NFE2L1 pathway in PD. A previous postmortem study has reported that the nuclear localization of NFE2L2, unlike that of NFE2L1 (in our study), is strongly induced in PD patients (Ramsey et al, 2007) , underlining a differential regulation of NFE2L1 and 2 ◀ Figure 5 . Identification of direct PBX1 target genes.
A Chromatin immunoprecipitation sequencing (ChIP-seq) identified a PBX1 binding core sequence motif composed of a 10-nucleotide motif (A) and a 5-nucleotide motif (B). B Schematic of the track of PBX1 ChIP-seq compared to IgG ChIP-seq as a control on different loci with peaks identified by HOMER. Each locus represents a 20-kb chromosome region. C List of the 29 most regulated genes (t-test q-value < 0.05) identified by Gene Set Enrichment Analysis (GSEA) and ranked by P-value. RPKM stands for reads per kilobase of transcript per million mapped reads. GSEA was performed on genes identified by RNA-Seq as differentially expressed in the VM at E12.5 compared to adjacent brain regions and identified by PBX1 Chip-Seq in proximity to transcription starting sites. D Graphic representation of these top 29 genes (red dots) in the GSEA curve showing a high correlation between the cistrome and transcriptome (P-value < 0.001, q-value < 0.005). E ChIP followed by PCR confirmed that PBX1 binds to genomic regions in close proximity to the TSS of Pitx3 (Pitx3-Gbf1), Onecut2, and Nfe2l1 genes. No coimmunoprecipitation was detected for the unrelated gene, Lrp1b (low-density lipoprotein receptor-related protein 1B). F, G The regulation of Pitx3 and Onecut2 by PBX1 was confirmed in Pbx1 The EMBO Journal PBX1 controls midbrain dopaminergic development J Carlos Villaescusa et al in PD. Importantly, our results suggest that NFE2L1 serves a physiological role in healthy mDAn of the substantia nigra and that its near complete absence in the nuclei of substantia nigra neurons in PD, impairs its function. Accordingly, we found that while increased PBX1 levels promote the survival and differentiation of human mDAn, reduced levels of NFE2L1 increase vulnerability to oxidative stress. We thus suggest PBX1 and NFE2L1 as novel targets for drug discovery, aimed at increasing neuroprotection in PD. In summary, our data highlight the important role of Pbx1 in the specification and maintenance of mDAn. Moreover, we identify that the PBX1-NFE2L1 pathway is a novel neuroprotective pathway that is dramatically compromised in PD patients. Thus, our results open the door for the future development of novel therapies for PD designed to alter the course of disease.
Materials and Methods
Animals
Wild-type embryos were obtained from CD1 and C57BL/6 mice strains. All mutant alleles used in this study were previously described: Pbx1 ); Pbx3 ; Pbx1 conditional mice (Ferretti et al, 2011) ; Th-Gfp (Matsushita et al, 2002) . As for deleter strains, Shh-Cre-ERT2 knock-in mice (Harfe et al, 2004) and Th-IRES-Cre-ERT2 (Rotolo et al, 2008; Badea et al, 2009) were used for Pbx1 inactivation in the VM or in mDA neurons. Mice were housed, bred, and treated in accordance with protocols approved by the local ethics committees (Stockholm's Norra Djurförsöketiska Nämnd N154/06, N88/07, N135/08, N145/ 09, N273/11 and, N326/12). All mutant mice were kept on a C57BL/6 background. Conditional pregnant females (between 3 and 7 months old) were treated with 4 mg tamoxifen per day (dissolved in corn oil) through oral gavage with animal feeding needles (Fisher Scientific, Waltham, MA) at 12 pm at 11.5, 12.5 and 13.5 days post-coitum.
Fetal tissue and patient sections
Human fetal tissue collection and processing ethical approval for the use of postmortem human fetal tissue was provided by the National Research Ethics Service Committee East of EnglandCambridge Central, UK (ethics number 96/085). All brain sections were obtained from the Cambridge Brain Bank. Information about their protocols and ethical committees can be found at http://www.cuh.org.uk/for-public/cambridge-brain-bank. We only considered sections from patients and controls in which nuclear immunoreactivity for NFE2L1 antibody was clearly detected, and used consecutive sections for PBX1 analyses. We excluded material in which no NFE2L1 immunoreactivity was detected in NM + or NM À cells.
In this study, the control group was PT151-76 years old (yo), male, no evident pathological condition PT190-85 yo, female, no evident pathological condition BB137/PT69-77 yo, female, with bilateral old lacunar infarcts, and no evidence of dementia.
For the PD group, P65-77 yo, male, with idiopathic PD, and some Alzheimer pathology, insufficient for a diagnosis in life PT161-73 yo, female, with idiopathic PD P67-70 yo, female, with idiopathic PD P69-81 yo, female, with idiopathic PD P70-85 yo, female, with idiopathic PD Gene and protein nomenclature
We followed the guidelines from the Human Genome Organization (HUGO) Gene Nomenclature Committee (HGNC) International Advisory Committee and the guidelines from the International Committee on Standardized Genetic Nomenclature for Mice. For mice, gene symbols are italicized, with only the first letter in uppercase and the remaining letters in lowercase (Pbx1). Protein designations are the same as the gene symbol, but are not italicized and all are upper case (PBX1). mRNAs use the same formatting conventions as the gene symbol.
For human, gene symbols are italicized, with all letters in uppercase (PBX1). Protein designations are the same as the gene symbol, but are not italicized and all letters are in uppercase (PBX1).
Immunofluorescence, immunochemistry, and in situ hybridization
For embryo analyses, heterozygous mice of the relevant genotype were mated overnight, and at noon of the day, the plug was considered E0.5. Briefly, embryos were dissected out of the uterine horns in ice-cold PBS, fixed in 4% paraformaldehyde (PFA) in PBS overnight, cryoprotected in 30% sucrose, and frozen in Tissue-Tek optimum cutting temperature (OCT) compound (Sakura Fine-Tek) on dry ice. Serial coronal 16 lm sections were used for immunohistochemistry or in situ hybridization.
For immunohistochemistry or immunofluorescence, all the sections were treated for antigen retrieval by microwave boiling in antigen retrieval solution (DAKO, S1699). Sections were washed in PBT (PBS with 0.5% Tween-20) and blocked in PBTA (PBS, 5% donkey serum, 0.3% Triton X-100, 1% BSA, except for human adult sections where the concentration of donkey serum was 10%). Primary antibodies were diluted in PBTA, and incubations were carried out overnight at 4°C. After washes in PBT, incubations with the appropriate secondary antibodies (Alexa, 1:500, Invitrogen, or horseradish peroxidase, The Jackson Laboratories) were carried out for 1 h at room temperature. For DAB staining with dark/blue coloration, addition of nickel and cobalt was added to the DAB solution.
Non-radioactive in situ hybridization was performed as previously described (Kele et al, 2006) . The mouse antisense RNA probes have been described previously (Ferretti et al, 2011) .
Antibodies used for immunofluorescence were as follows: rabbit anti-NURR1 (sc-990, 1:500, Santa Cruz Biotechnology); goat anti-NURR1 (AF2156, 1:500, R&D); rabbit anti-TH (P40101-0, 1:500; PelFreeze); sheep anti-TH (NB300-110, 1:500, Novus Biologicals); mouse anti-TH (22941, 1:500; Immunostar); rabbit anti-LMX1A 
Western blot
For Western blot analysis, samples were subjected to 10% SDS-PAGE, electrotransferred onto Hybond-P membrane, immunodetected using appropriate primary and secondary antibodies, and visualized by ECL+Plus reagents according to the manufacturer's instructions (Amersham). Antibodies used were as follows: polyclonal rabbit anti-NRF1 (NFE2L1, Santa Cruz, H-285, sc-13031), mouse anti-beta-Actin (Abcam, ab8226), and mouse anti-GAPDH (G8795, Sigma).
Blots were analyzed using a BIO-RAD Molecular Imager ChemiDoc XRS+ Imaging system.
Chromatin immunoprecipitation (ChIP)
Ventral midbrain E12.5 tissues were trypsinized to a single-cell suspension using TrypLE (Invitrogen). Cells were filtered and washed using cold PBS with 1% BSA. Chromatin immunoprecipitation assays were performed following the manufacturer's instructions (Pierce, Agarose ChIP kit; 26156). The chipped fragmented DNA samples obtained from the ChIP were end repaired and A-tailed. Then, the Illumina adapters were ligated and size selected (200-350 bp) from the gel before going to PCR amplification. The PCR samples were purified and size selected again in the gel. The final eluted samples from the gel were sequenced in Genome Analyzer IIx. Both the samples and input were loaded in a single lane (used two different barcode to track two different samples). Single-end sequencing reads were generated from the final cDNA libraries. The final outcome sequences were aligned to the mouse genome. Peak detection was performed using the HOMER base suite v4.3 (Heinz et al, 2010) with a false discovery rate filter of 5% utilizing the read from PBX1-ChIP-seq, normal IgG ChIP-seq normalized to inputs. The top 10% of the peaks were used for de novo motif finding using the MEME-ChIP tool from MEME suite (Machanick & Bailey, 2011) (http://meme-suite.org/) with default settings and the HOMER-based suite (Heinz et al, 2010) .
The peak-gene association was done using GREAT v2.0.2, associating a genomic region with the two nearest genes (McLean et al, 2010) . Peaks heatmap was done using SeqMiner 1.3.3 (Ye et al, 2011) with default settings. Gene set enrichment analysis (GSEA) was performed as described previously (Subramanian et al, 2005) , with genes scored according to their signal to noise metric of expression in the ventral midbrain vs. the other samples and custom gene sets for PBX1 ChIP-seq results. ChIP-seq representation of reads was made using the integrative genome browser (Robinson et al, 2011) . ChIP-seq data are deposited in the public NCBI GEO database with accession number GSE82098 and GSE82100.
Locus classification and analysis
Genes of the GSEA with a running enrichment score that was positive were listed as genes upregulated by PBX1. Genes with running enrichment scores that were after the minimum (leading edge) were classified as genes repressed by PBX1. The genes peaks were classified as enhancer if at least one of the genes were upregulated, classified as repressor if at least one was downregulated. Peaks on which one gene was upregulated and the other downregulated were classified as divergent. Transcription factor binding site enrichment was performed using the oPOSSUM-3 single-site analysis software with all genes as background, and the Jaspar Core profiles (PortalesCasamar et al, 2010) with the rest of the options as default (Kwon et al, 2012) . Motif comparison was made using the TOMTOM software (Gupta et al, 2007) of the MEME suit (Bailey et al, 2015) .
Tru-Seq
Different parts of embryonic (E12.5) mouse brains (Th-Gfp strain) were dissected under the microscope. RNA was extracted from the collected tissue according to a Trizol RNA isolation protocol (Life Technology). The starting RNA material to construct cDNA libraries from each sample was 200 ng. cDNA libraries were prepared according to Illumina's Tru-Seq DNA sample preparation guide. Ten enriched libraries (duplicate samples from five different parts of the brain) were subjected to Illumina sequencing in one lane of HiSeq 2000. The sequencing reads were sorted by barcode and then mapped into the mouse genome (mm9) using Bowtie short read aligner. The data were analyzed using Qlucore omics explorer. RNAseq data are deposited in the public NCBI Gene Expression Omnibus (GEO) database with accession number GSE82099 and GSE82100.
Mass spectrometry analysis
The antibody against PBX1 used for ChIP (rabbit, #43428, 1:500, Cell Signaling) was validated by mass spectrometry, identifying PBX1 protein as the main immunoprecipitated protein, using E14.5 VM extracts. Protein bands were excised manually from a silverstained SDS-PAGE gel and de-stained, reduced, and trypsin-digested in a robotic protein handling system (MassPREP station, Waters, Milford, MA). Tryptic peptides were extracted with 30 ll of 5% formic acid/2% acetonitrile and subsequently with 24 ll 2.5% formic acid/50% acetonitrile. Protein fragments were separated using a nanoAcquity HPLC system (Waters, Milford, MA) and sequenced using collision-induced dissociation in a quadruple timeof-flight mass spectrometer (Q-TOF Premier API, Waters, Milford, MA, USA) with a standard Z-spray source. Data analysis was performed using ProteinLynx Global SERVER 2.3 software (Waters, Milford, MA) . Lockmass reference of a [Glu1] fibrinopeptide B (Sigma, St. Louis, MO, USA) was used for mass scale correction when processing the data.
Cell lines
For maintenance of hNES cells (AF22 line, iPSC-derived (Falk et al, 2012) ), AF22 cells are kept in 6-well plates coated with laminin (1:500 in water, Invitrogen, 23017-015) and poly-L-ornithine (PLO, 1:5 in water; Sigma), in maintenance medium (N2 supplement (1:100, Gibco), B27 supplement (1:1,000, Gibco), FGF2 (10 ng/ml, R&D), and bFGF (10 ng/ml, R&D).
For differentiation of hNES cells, they are dissociated (TrypLE Select), seeded in 48-well plates coated with laminin and PLO (100,000 cells per well), and cultivated for 2 days with N2 (1:100), B27 (1:1,000), SHH (200 ng/ml, R&D), and CT99021 (1 lM). After that, cells were kept on media containing N2 (1:100), B27 (1:100), GDNF (20 ng/ml, R&D), and BDNF (20 ng/ml, R&D).
SN4741 cells were maintained as previously described (Son et al, 1999) .
Cell lines were routinely tested for mycoplasma contamination. The AF22 line was authenticated recently (Falk et al, 2012) . SN4741 line was not authenticated by any method.
Cloning, lentivirus production, and infection
Human PBX1 cDNAs were cloned into the lentiviral backbone Tet-O-Fuw using the EcoRI restriction site present on the vector. The cDNAs were amplified with the following primers: hPbx1 EcoRI Fwd: ggccGAATTCATCGACGAGCAGCCCAGGC hPbx1 EcoRI Rev: ccggGAATTCTCAGTTGGAGGTATCAGAGTG
The Tet-O-Fuw-hPBX1 and FUW-rtTA (Addgene 20342) lentiviruses were produced in HEK293FT packaging cells (Invitrogen) cultured in DMEM with 10%FBS and penicillin/streptomycin. On the day prior to the transfection, HEK293FT cells were plated in order to reach a 70-80% confluence on the next day. On the following day, the cells were transfected using the XtremeGene9 transfection reagent (Roche) according to the manufacturer's instructions. The Tet-O-Fuw plasmids harboring hPBX1 and the FUW-rtTA plasmid were individually cotransfected with the vectors pMDLg/pRRE (Addgene 12251), pRSV-Rev (Addgene 12253), and pMd2.G (Addgene 12259) in a 4:2:1:1 ratio, respectively. The transfection mix was removed after an overnight incubation, and fresh media were supplied to the cells. The volume of the fresh media was just sufficient to cover the cells and avoid their dehydration. Thirty hours after transfection, the media of the cells were collected and centrifuged for 5 min at 435 g in order to separate the supernatant from cellular debris. The supernatants were then centrifuged for 2 h and 30 min at 60,000 g at 4°C in a Beckman Coulter Avanti-JE Centrifuge. The resulting pellets were slowly resuspended in PBS over 2 hours, then aliquoted, and kept at À80°C.
The three viruses were subsequently titrated using the Lenti-X Provirus Quantitation Kit (Clontech) in SVGp12 cells (ATCC) according to the manufacturer's instructions.
hNES cells were infected in their normal culture medium overnight, while the SN cells were infected in their normal culture medium supplemented with 8 lg/ml of polybrene for 24 h.
ShRNA experiments
NFE2L1 (NRF1) shRNA lentiviral particles (sc-43575-V, Santa Cruz Biotechnology Inc.) are a pool of concentrated, transduction ready viral particles containing 3 target-specific constructs that encode 19-25 nucleotides (plus hairpin) shRNA designed to knock down human NFE2L1 gene expression. The volume selected to treat 1 single well of a 48-well plate was 10 ll, corresponding to 50,000 infection units of virus (each vial contains 1.0 × 10 6 infectious units of virus in 200 ll). As a negative control for experiments, we used the shRNA lentiviral particles (sc-108080, Santa Cruz Biotechnology Inc.), which encodes a scrambled shRNA sequence that does not lead to the specific degradation of any known cellular mRNA.
RT-PCR
All the reagents were purchased from Invitrogen. The following oligonucleotides (Eurofins MWG Operon and/or SIGMA) were used to amplify the genomic regulatory region identified in our ChIP experiments: 
Quantification of chromogen intensity in PBX1 immunohistochemistry
For quantification of PBX1 intensity of a chromogen stain under bright field microscopy, we used a method previously described (Nguyen et al, 2013) . Briefly, we considered that standard bright field red-green-blue color images have a maximum intensity of value 250 (intensity function in ImageJ software). Darker areas have lower intensity values. This results in an inverse correlation between the amount of antigen and its numerical value. The intensity of a stained region in an RGB image analyzed in ImageJ can be subtracted from 250, obtaining a value that is directly proportional to the amount of chromogen present. We selected a round area of 328 square pixels and placed, when possible, in the nucleus of each NM + cell. The value obtained from ImageJ (mean) was used to calculate the new value (250-mean) for each cell, proportional to the amount of chromogen present in the nucleus.
Statistics
Sample size for embryonic analyses was chosen according to previous studies in the same area of research. A minimum of 3 embryos was analyzed for each genotype for comparison. The only exclusion criterion was an evident developmental delay between embryos of different genotypes. The exclusion criterion was preestablished. No randomization or blinding procedure was used for animal studies. Although we cannot be certain that our data in the population has a normal distribution, we considered our data as being close to Gaussian distribution and applied two-tailed unpaired t-tests for comparison between two groups of samples, without assuming similar variance. This is a common standard in the field, and a t-test is commonly used in other similar studies. No special steps were taken to minimize the effects of subjective bias when animals or cells were under treatment. Two-tailed unpaired t-test statistical analyses were performed using GraphPad Prism 6. Bars represent mean AE standard deviation. Biological replicates (dot) per condition and P-value of t-test are indicated in each graph.
Expanded View for this article is available online.
